Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Details

NCT ID

NCT06801236

Phase

PHASE1

Sponsor

Acerand Therapeutics (Hong Kong) Limited

Status

RECRUITING

Cancer Type

Castration-Resistant (CRPC) Prostate Cancer

Interventions

• ACE-232 tablets

Locations (sample)

• La Jolla, California, United States|32.84727,-117.2742
• Tampa, Florida, United States|27.94752,-82.45843
• Baltimore, Maryland, United States|39.29038,-76.61219
• Boston, Massachusetts, United States|42.35843,-71.05977
• Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

• Provide written informed consent
• Metastatic Castration-resistant Prostate Cancer with ongoing androgen - deprivation therapy (ADT) or have bilateral orchiectomy
• Difficult to treat or intolerant to standard treatment (post at least 1 line of NHA and taxane-based chemo in mHSPC or mCRPC), suitable for investi…
• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.